Bristol Myers Squibb’s (BMS) combination treatment for renal cell cancer missed its primary endpoint of disease-free survival in the phase 3 CheckMate-914 trial, Part A, the company reported.
Source: Drug Industry Daily
Bristol Myers Squibb’s (BMS) combination treatment for renal cell cancer missed its primary endpoint of disease-free survival in the phase 3 CheckMate-914 trial, Part A, the company reported.
Source: Drug Industry Daily